The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Metadata

Authors/Creators:
Dates:
  • Published: 1 June 2022
Institution: The University of Leeds
Funding Information:
FunderGrant number
Cancer Research UK Supplier No: 138573C7852/A19772
Leeds Teaching Hospitals Charitable FoundationFund No IT01
Cancer Research UK Supplier No: 138573RCS REF 08-0843 SUBCONTR
Cancer Research UK Supplier No: 138573C6003/A7367
Leeds Hospitals Charity1T01-A321
Leeds Teaching Hospitals Charitable Foundation4616
Cancer Research UK Supplier No: 138573C6003/A15546
Amgen Limited ***USE 819922***NOT GIVEN
MRC (Medical Research Council)2012-005111-12
NIHR National Inst Health Research2012-005111-12
Depositing User: Symplectic Publications
Date Deposited: 21 Nov 2022 13:57
Last Modified: 21 Nov 2022 13:57
Status: Published
Identification Number: https://doi.org/10.1200/JCO.2022.40.16_suppl.3540
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)